Azelis enters into important distribution agreement with Novo Nordisk Pharmatech
25 May 2017
Azelis has entered into an agreement with Novo Nordisk Pharmatech A/S for the distribution of pharmaceutical grade quaternary ammonium compounds (quats) to the pharmaceutical and medical device markets in Germany, Spain, Portugal, UK and Ireland.
Matthew Dickman, Market Segment Director Pharma Azelis explains: “Novo Nordisk Pharmatech is the industry leader in pharmaceutical grade quats and we are delighted they have chosen Azelis Pharma as their distribution partner for the development of these markets. Novo Nordisk Pharmatech’s quats complement an existing Azelis portfolio of pharma antimicrobials. Alongside established uses of quats, our pharma experts see potential new applications in the growing wound care market. Our local teams, who work with customers to support both their current and NPD requirements, will be investigating these options in the coming period.”
Novo Nordisk Pharmatech manufactures its quats (Benzalkonium, Cetrimide and Cetyl Trimethyl Ammonium Bromide, including customised grades) to the highest (c)GMP standards. Their site (Koge, Denmark) is audited by the Danish Medicines Agency and US-FDA. Products comply with the latest major pharmacopoeia and are supported by CEPs, DMFs and a comprehensive package of regulatory and quality assurance documents.
“We are very happy to work with Azelis as our distribution partner for pharmaceuticals. Novo Nordisk Pharmatech’s FeF™Quats products fit perfectly with Azelis existing antimicrobial portfolio enabling the customers to take advantage of these synergies. We wish to give the best service to our customers and the local pharma teams of Azelis are experts in working with customers to support their current and new product development requirements,” says Steve Profit, Sales & Marketing Director at Novo Nordisk Pharmatech A/S.